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ABSTRACT
Objectives: To analyse the effect of dydrogesterone use during pregnancy on uterine fibroids, pregnancy complications, 
and pregnancy outcome.
Material and methods: In all, 372 pregnant women with uterine fibroids who were treated at the Affiliated Provincial 
Hospital of Shandong University were included in this study. Thirty-three of these women received dydrogesterone and 
constituted the treatment group, and the 27 women who were found to have uterine fibroids during the first trimester but 
did not receive intervention to prevent miscarriage composed the control group. The changes in uterine fibroids before 
and after pregnancy and the pregnancy complications were recorded; immunohistochemistry was used to detect the 
expression of progesterone receptor (PR) and proliferation- and apoptosis-related proteins in the uterine fibroid tissue. 
Results: No significant difference was observed in the change in uterine fibroid volume during pregnancy between the 
treatment group and the control group (p > 0.05). The percentage of uterine fibroids with red degeneration was lower in 
the treatment group than in the control group, but the difference was not statistically significant. No significant difference 
was observed in newborn weight, height, Apgar score, threatened miscarriage, or premature birth, among other charac-
teristics, between the two groups (p > 0.05). Immunohistochemistry showed no significant difference in the expression of 
PR, cyclinD1, insulin-like growth factor (IGF1), or B-cell lymphoma 2 (Bcl2) between the two groups.
Conclusions: The use of dydrogesterone during pregnancy has no significant effect on uterine fibroids, pregnancy progres-
sion, or pregnancy outcomes in pregnant patients with uterine fibroids.
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INTRODUCTION
Most cases of uterine fibroids occur in women of child-
-bearing age with strong ovarian function; thus, uterine 
fibroids are closely related to pregnancy. The incidence of 
pregnancy with uterine fibroids has continued to increase 
year after year and has attracted a great deal of attention 
[1, 2]. Studies have reported that up to 10.7% of pregnant 
women have uterine fibroids [3]. However, the relationship 
between uterine fibroids and adverse pregnancy outcomes 
is unknown. The effect of uterine fibroids on pregnancy 
depends on the size and location of the fibroids. Proper 
treatment of uterine fibroids that cause infertility might, to 
some extent, affect the outcomes of the next pregnancy.
Uterine fibroids are hormone-dependent. Due to the 
significant fluctuations in hormone levels during pregnancy, 
the size and nature of uterine fibroids, of which there are diffe-
rent types and locations, may change. For pregnant women, 
the growing uterus may cause torsion of pedunculated sub-
serosal fibroids, and uterine fibroids at the uterine isthmus 
or the posterior lip of the uterine cervix may block the birth 
canal. Moreover, uterine fibroids may affect uterine contrac-
tions and prevent natural placental separation after delivery, 
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which may cause postpartum haemorrhage. Our previous 
study demonstrated that resection of uterine fibroids during 
caesarean section does not affect the incidence of pregnan-
cy complications such as postpartum haemorrhage [4]. 
However, pregnant women with uterine fibroids are at a hi-
gher risk for perioperative complications, and numerous 
studies have demonstrated that uterine fibroids are related 
to pregnancy complications, such as miscarriage, premature 
birth, premature placental separation, malpresentation, 
and low newborn weight. The incidence of these compli-
cations varies but, nevertheless, has continued to rise year 
by year [5].
Dydrogesterone (Duphaston) is commonly used to 
prevent miscarriage in pregnant women with threatened 
miscarriage before gestational week 20. Clinical studies have 
shown that Duphaston exhibits effects similar to those of 
adrenal hormones, oestrogen, and androgens. Studies have 
demonstrated that the progesterone receptor (PR) is highly 
expressed in uterine fibroid tissue, whereas progesterone 
agents cause an elevation in the mitochondrial membrane 
potential, and ultimately, abnormal cell proliferation [6]. 
In addition, studies have shown that PR directly activa-
tes and acts on relevant signalling pathways to cause cell 
proliferation in uterine fibroids [7]. Currently, researchers 
believe that uterine fibroids rely on the synergistic effect of 
ovarian steroid hormones, oestrogen, and progesterone for 
their development and progression and that progesterone 
may play a more critical role than oestrogen. To date, no 
in-depth studies have been conducted to investigate the 
specific effect of Duphaston on uterine fibroids.
To investigate the effect of Dydrogesterone on uterine 
fibroids during pregnancy, pregnancy complications, and 
pregnancy outcomes in pregnant women with uterine fibro-
ids, we analysed fibroid growth, pregnancy outcomes, and 
pregnancy complications in pregnant women with uterine 
fibroids with or without Duphaston treatment to prevent 
miscarriage. The purpose was to obtain clinical guidance for 
the use of Duphaston (to prevent miscarriage) in pregnant 
women with uterine fibroids.
MATERIAL AND METHODS
This study was approved by the local research Ethics 
Committee of Shandong Provincial Hospital in Jinan, China.
General information
In all, 372 pregnant women with uterine fibroids treat-
ed at Affiliated Provincial Hospital of Shandong University 
between November 2013 and June 2015 were included 
in this study; of these women, 82 required intervention 
during pregnancy to prevent miscarriage for various rea-
sons, including the following: red degeneration of uterine 
fibroids per an abdominal B ultrasound scan during preg-
nancy (n = 12; usually presenting with severe sudden lower 
abdominal pain, which may be accompanied by fever and 
vomiting), hypothyroidism (n = 2), subclinical hypothyroid-
ism during pregnancy examination (n = 2), threatened mis-
carriage due to incompliance with the dose adjustment of 
levothyroxine tablets during pregnancy, threatened miscar-
riage due to antiphospholipid antibody syndrome (n = 1), 
severe gestational vomiting (n = 1), gestational diabetes 
(n = 8), gestational hypertension (n = 10), premature rupture 
of membranes (n = 9 ), placental abnormalities (n = 2), and 
unexplained vaginal bleeding and lower abdominal pain 
(n = 43) (Tab. 1). 
Among the 372 pregnant women with uterine fibroids, 
82 received intervention to prevent miscarriage. Among 
them, 33 women with indications during the first trimester 
received oral Duphaston 20 mg/day for 2 months or longer 
and did not receive other drugs (the treatment group), 
and 27 were found to have uterine fibroids during the first 
trimester but did not receive intervention to prevent miscar-
riage (the control group). Patients in both groups underwent 
a caesarean section. General clinical information was com-
pared between the two groups, including the gestational 
age of the current pregnancy, the number of miscarriages, 
gestational age, body mass index (BMI), and fibroid size dur-
ing the first trimester. A B ultrasound scan was performed to 
measure the maximum diameter (cm) of the fibroid during 
the first trimester. BMI = weight (kg)/height2 (m2). Maternal 
weight and height were measured at the time of admission 
for labour.
Immunohistochemical staining 
For all patients, uterine fibroids were resected during 
caesarean section. Fibroids were paraffin-embedded and 
prepared as 5-μm-thick sections for immunohistochemical 
Table 1. Analysis of the pathogeny of pregnant women with uterine 
fibroids 
Pathogeny N Percentage (%)
Red degeneration of uterine fibroids 
(diagnosed by abdominal B ultrasound scan) 12 14.63
Hypothyroidism 2 2.44
Antiphospholipid antibody syndrome 1 1.22
Severe gestational vomiting 1 1.22
Gestational diabetes 7 8.54
Gestational hypertension 5 6.10
Premature rupture of membranes 9 10.89
Placental abnormalities 2 2.44
Unexplained vaginal bleeding and lower 
abdominal pain 43 52.44
Total 82 100
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staining to determine the PR, cyclinD1, insulin-like growth 
factor 1 (IGF1), and B-cell lymphoma 2 (Bcl2) expression 
in the two groups. Next, the sections were deparaffinized 
and rehydrated, and 0.5% Triton X-100 was used to rupture 
the membranes. Then, warm 0.01 M citrate buffer (pH 6.0) 
was used for antigen retrieval for 15 minutes, and the sec-
tions were immersed in 3% hydrogen peroxide (diluted in 
methanol) for 20 minutes to inactivate endogenous catalase. 
Next, 10% normal goat serum was used to block the sec-
tions, and then the primary antibody (1:100) was added for 
an overnight incubation at 4°C. IgG (same dilution) was used 
as the primary antibody for the negative control. After PBS 
washes (3 times × 5 minutes), the sections were incubated 
with a biotinylated goat anti-rabbit or goat anti-mouse 
secondary antibody (Wuhan Boster Biological Technology, 
Ltd.) at a dilution of 1:200 at room temperature for 40 min-
utes. After DAB staining and haematoxylin counterstain-
ing, the sections were observed and photographed under 
an Olympus microscope. Five fields (× 400) were randomly 
selected to analyse the staining density of the cytoplasm 
and the nucleus. The final immunohistochemical staining 
score (0–12) = density value × percentage score.
Statistical analysis
A WPS table was used to establish the database, and 
SPSS20.0 (Statistical Product and Service Solutions 20.0) 
statistical software was used for the data analysis. Numeri-
cal data are expressed as the mean ± standard deviation 
(SD) (x ± s); an independent sample t-test was performed 
for between-group comparisons, and a chi-squared test 
was performed to compare the incidence between the two 
groups.
For the immunohistochemistry results, brown particles 
indicated positive staining, and the semi-quantitative analy-
sis that was performed incorporated the staining intensity 
and the scope of distribution. The staining intensity was 
rated as follows: 0: no staining, 1: light staining, 2: moderate 
staining, and 3: strong staining. The scope of distribution 
was rated as follows: 0: positive percentage of 0%, 1: 1% to 
25%, 2: 25% to 50%, 3: 51% to 80%, and 4: 81% to 100%. The 
product of these two scores indicated the protein expression 
level. A two-tailed Student’s t-test was performed to analyse 
the difference in immunohistochemical staining between 
the two groups. The data are expressed as the mean ± SD. 
P < 0.05 was considered statistically significant.
RESULTS
General information of the patients 
The general clinical information, including the gesta-
tional age of the current pregnancy, the number of mi-
scarriages, gestational age, BMI, and fibroid size during 
the first trimester, was compared between the treatment 
group (n = 32) and the control group (n = 27). No significant 
differences were observed (all p > 0.05) (Tab. 2).
Changes in uterine fibroids after caesarean 
section
Fibroid size was indicated as the maximum diameter (cm), 
and ΔΦ (diameter variation) was used to indicate the change 
in fibroid size before and after caesarean section, wherein 
ΔΦ = fibroid diameter at the time of caesarean section — fi-
broid diameter during the first trimester. For the treatment 
group, the mean fibroid diameter was 3.44 ± 2.70 cm dur-
ing the first trimester and 7.11 ± 2.38 cm at the time of 
caesarean section (ΔΦ1 = 3.66 cm). For the control group, 
these values were 3.37 ± 2.65 cm and 7.57 ± 1.35 cm during 
the first trimester and at caesarean section, respectively 
(ΔΦ2 = 4.20 cm) (Tab. 3). In both groups, the uterine fibroids 
were significantly larger at the time of caesarean section 
than during the first trimester (both p < 0.01), but no signifi-
cant difference was observed in the change in the uterine 
fibroid volume between the two groups (p > 0.01) (Tab. 3).
Effect of Duphaston on the red degeneration  
of uterine fibroids 
Routine pathological examination showed that the sec-
tion of degenerated fibroids was red and soft and that the 
swirl structure had disappeared. Microscopic observation 
Table 2. General clinical information of the patients treated with 
Dydrogesterone and those who were not
General information
Treatment 
subjects
(n = 33, x ± s)
Control 
subjects
(n = 27, x ± s)
p
Gestational age 32.40 ± 4.11 32.74 ± 4.74 > 0.05
Number of 
miscarriages 1.00 ± 1.27 0.78 ± 0.84 > 0.05
Gestational week 37.82 ± 2.68 38.47 ± 1.47 > 0.05
BMI [kg/m2] 29.08 ± 3.24 28.62 ± 2.72 > 0.05
Fibroid size during the 
first trimester [cm] 3.44 ± 2.70 3.37 ± 2.65 > 0.05
Table 3. Changes in uterine fibroids during pregnancy
Fibroid size Treatment subjects(n = 33, x ± s)
Control subjects
(n = 27, x ± s)
Fibroid diameter during 
the first trimester [cm] 3.44 ± 2.70 3.37 ± 2.65
At the time of 
caesarean section [cm] 7.11 ± 2.38
# 7.57 ± 1.35#
Size change [cm] 3.66 ± 1.44 4.20 ± 2.14
Note: #p < 0.01
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showed tissue oedema, small vein thrombosis in the tumo-
ur, vascular dilatation and congestion, extensive bleeding 
and haemolysis, a low number of muscle cells, and nuclei 
dissolution and disappearance. Pathological diagnosis re-
vealed that in the treatment group (intervention was given 
to prevent miscarriage) (n = 33), 20 patients (60.61%) had 
red degeneration of uterine fibroids, 7 (21.21%) had no 
red degeneration, and the remaining patients had other 
types of degeneration; in the control group (n = 27), 21 pa-
tients (77.78%) had red degeneration of uterine fibroids, 
3 (11.11%) had no red degeneration, and the remaining 
patients had other types of degeneration. The incidence of 
red degeneration of uterine fibroids was lower in the tre-
atment group than in the control group, but the difference 
was not statistically significant (p > 0.05) (Fig. 1).
Pregnancy complications  
and pregnancy outcomes
The percentage of premature rupture of membranes 
and abnormal foetal position was higher in the treatment 
group than in the control group; the percentage of foetal 
distress, placenta previa, postpartum haemorrhage, and 
large foetus was lower in the treatment group than in the 
control group. The newborn weight, height, and delivery 
time (in hospital) were larger or longer in the treatment gro-
up than in the control group, and the intraoperative blood 
loss and operative time were lower or shorter, respectively, 
in the treatment group than in the control group. However, 
the differences were not statistically significant (all p > 0.05) 
(Tab. 4a, 4b). No premature birth or foetal abnormalities 
were observed in the two groups.
Expression of PR and proliferation-  
and apoptosis-related proteins in uterine fibroid 
tissue obtained from pregnant women during 
caesarean section 
We first performed immunohistochemical staining to 
evaluate the PR expression in uterine fibroid cells. Figu-
25
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Red degeneration of uterine broids
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20
13
21
6
p = 0.16
No red degeneration
Figure 1. Red degeneration of uterine fibroids in pregnancy.  
Note: In the treatment group (dydrogesterone was given to prevent 
miscarriage), 20 patients (60.61%) had red degeneration of uterine 
fibroids, and 13 had no red degeneration; in the control group, 21 
patients had red degeneration of uterine fibroids, and 7 had no red 
degeneration. The incidence of red degeneration of uterine fibroids 
was lower in the treatment group than in the control group, but the 
difference was not statistically significant (p = 0.16)
Table 4a. Pregnancy complications
Complications
Treatment subjects (total 33) Control subjects (total 27)
p
n % n %
Premature rupture of membranes 3 9.09 2 7.41  > 0.05
Abnormal foetal position 2 6.06 1 3.70  > 0.05
Foetal distress 1 3.03 1 3.70  > 0.05
Placenta previa 1 3.03 1 3.70  > 0.05
Postpartum haemorrhage 1 3.03 1 3.70  > 0.05
Large foetus 1 3.03 2 7.41  > 0.05
Table 4b. Pregnancy outcomes
Outcomes Treatment subjects (n = 33) Control subjects (n = 27)  p
Blood loss [mL] 271.52 ± 124.98 324.07 ± 105.95  0.09
Operative time [min] 121.66 ± 37.62 127.59 ± 30.17  0.51
Time in hospital (days) 6.48 ± 3.21 5.48 ± 1.09  0.13
Apgar score (score) 10.00 ± 0.00 10.00 ± 0.00  –
Newborn height [cm] 48.24 ± 1.90 48.04 ± 3.06 0.22
Newborn weight [g] 3480.76 ± 461.38 3309.37 ± 531.74 0.08
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Figure 2. Expression of PR and proliferation- and apoptosis-related 
proteins in the control group and the treatment (Duphaston) group 
Note: In this study, we performed immunohistochemical staining to 
evaluate the expression of PR, cyclinD1, IGF1, and Bcl2 in the control 
and treatment groups. The results showed no significant difference in 
protein expression between the two groups
A
B
Table 5. Comparison of PR expression in uterine fibroid tissue
Tissue n
 PR
p
 + ++ +++ PR expression detected (%) 
Study subjects 32  3 10 15 87.5
0.488
Control subjects 27  5 7 9 77.8
Note: PR expression was found in 87.5% of patients in the treatment group, but the difference between the two groups was not statistically significant (p > 0.05)
re 2 shows no significant difference in PR expression in 
the nucleus between the treatment group and the control 
group, which indicates that Duphaston had no effect on 
PR expression in the nucleus. PR expression was found in 
87.5% of patients in the treatment group, which was higher 
than the percentage in the control group (77.8%), but the 
difference was not statistically significant (p > 0.05) (Tab. 5).
We examined the expression of the proliferation-related 
genes cyclinD1 and IGF1. Duphaston had no significant 
effect on cyclinD1 or IGF1 expression, which was consistent 
with our clinical experience (no significant increase in fibroid 
size was observed after Duphaston treatment).
We determined the Bcl2 expression in the treatment 
(Duphaston) group and the control group but observed 
no significant difference between the two groups (Fig. 2). 
DISCUSSION
Progesterone and uterine fibroids 
Numerous clinical studies and experiments have shown 
that uterine fibroids are hormone-dependent. Recent stu-
dies have shown that progesterone promotes uterine fibroid 
proliferation and inhibits apoptosis, thereby promoting 
fibroid growth [8]. Oestrogen and progesterone promote 
fibroid growth in different ways. During pregnancy, the 
level of maternal oestrogen and progesterone increases 
significantly, which provides the appropriate conditions for 
fibroid growth. Currently, it is unclear whether the use of 
agents such as progesterone during pregnancy to prevent 
miscarriage may promote fibroid growth or increase the 
occurrence of red degeneration in uterine fibroids.
Effect of progesterone on uterine fibroids  
during pregnancy
In the past three decades, researchers have debated the 
effect of pregnancy on uterine fibroid volume. Numerous 
researchers have conducted relevant research but have 
reached different conclusions [9]. 
De ViVo et al. [10] revealed that the volume of uterine 
fibroids significantly increased during pregnancy. Rosati et 
al. [11] showed that the uterine fibroid volume increased 
during the first trimester, did not continue to increase du-
ring the second and third trimesters, and decreased after 
Control Duphaston
PR
Cy
cl
in
 D
1
IG
F1
Bc
l2
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birth. Some studies have indicated that during pregnancy, 
uterine fibroids grew at a rate of 0.667 mm per week during 
the first and second trimesters [12]. Benaglia et al. [13] also 
showed that the uterine fibroid volume increased rapidly 
and significantly during the first trimester.
Most studies showed that uterine fibroids grew during 
pregnancy; however, some studies reported that during 
pregnancy, the uterine fibroid volume decreased or rema-
ined unchanged. Ozturk et al. [14] reported no significant 
change in the volume of uterine fibroids during pregnancy. 
Neiger et al. [15] conducted a longitudinal study of 137 pre-
gnant women with uterine fibroids and found that very few 
patients showed an increase in uterine fibroid volume (per 
ultrasound). Phelan et al. [16] suggested that the level of 
circulating progesterone was significantly higher during 
pregnancy, but most pregnant women with uterine fibro-
ids did not show an increase or even a decrease in uterine 
fibroid volume during pregnancy.
In this study, we compared the general clinical informa-
tion between the treatment group and the control group. 
We observed no significant difference between the two 
groups. This study showed that uterine fibroids were signi-
ficantly larger at the time of caesarean section (end of third 
trimester) than during the first trimester in both groups; ho-
wever, the change in the uterine fibroid volume before and 
after caesarean section did not significantly differ between 
the two groups. Therefore, although the volume of uterine 
fibroids increased significantly during pregnancy, the use of 
progesterone (to prevent miscarriage) did not significantly 
increase the uterine fibroid volume in pregnant women.
Progesterone promotes the proliferation of uterine fi-
broid cells [7]. Our results showed that Duphaston had no 
significant effect on the expression of cyclinD1 or IGF1. This 
was consistent with our clinical experience, which showed 
no significant increase in fibroid size after Duphaston treat-
ment. Moreover, we determined the expression of Bcl2 in the 
treatment group (Duphaston) and the control group, and no 
significant difference was observed between the two gro-
ups. This finding contradicted previous reports, which showed 
that progesterone inhibited apoptosis [8]. This contradiction 
may be related to the small sample size in this study. 
Red degeneration of uterine fibroids  
during pregnancy
During pregnancy, uterine fibroids may undergo red 
degeneration due to the unstable state of the coagulation 
and fibrinolysis system. Studies in pregnant women with 
degenerated uterine fibroids showed that high-dose natu-
ral progesterone affected the blood vessels, increased the 
blood flow in fibroids, and relieved the acute abdominal 
syndrome caused by fibroid degeneration, with an intraope-
rative finding of shrinkage or disappearance of the original 
degenerated fibroids [17]. The present study showed red 
degeneration in 60.61% of uterine fibroids in the treatment 
group (progesterone to prevent miscarriage), which was 
lower than in the control group, but the difference was not 
statistically significant. In addition, PR expression was found 
in 87.5% of patients in the treatment group, which was hi-
gher than the percentage of patients in the control group 
(77.8%), but the difference was not statistically significant. 
This finding may be related to the small sample size in this 
study; nevertheless, the present study demonstrated that 
Duphaston treatment did not increase the occurrence of red 
degeneration of uterine fibroids during pregnancy.
Effect of progesterone on pregnancy 
complications and pregnancy outcomes
Progesterone is an important steroid hormone that 
functions to maintain pregnancy during the first trimester. 
Studies have shown that progesterone prevents premature 
birth and helps to prevent miscarriage in pregnant women 
with a short cervix. However, the mechanism by which pro-
gesterone prevents premature birth or prolongs gestation 
is unknown. The conventional belief is that progesterone 
prevents miscarriage via the inhibition of preterm contrac-
tions of uterine muscle fibres or via the inhibition of the 
expression of factors involved in uterine contractions in 
the myometrium, such as prostaglandin, oxytocin receptor, 
and gap protein [18]. Increasingly, researchers believe that 
progesterone exerts both immunomodulatory and anti-
-inflammatory effects [19].
Some researchers believe that progesterone may cause 
the placenta to adhere too tightly, making it difficult to 
separate during labour, thus contributing to postpartum 
haemorrhage. Some meta-analyses found no significant 
difference in maternal or foetal adverse reactions between 
the progesterone (to prevent miscarriage) group and the 
control group [20, 21]. The present study demonstrated 
that the use of dydrogesterone during the first trimester to 
prevent miscarriages had no adverse effects on pregnancy 
complications and pregnancy outcomes.
In summary, this was the first study to investigate the 
effect of dydrogesterone on uterine fibroids during pre-
gnancy, pregnancy complications, and pregnancy outco-
mes. We conducted several analyses of clinical and labo-
ratory specimens and demonstrated that dydrogesterone 
(to prevent miscarriage) had no significant effect on the 
change in uterine fibroids during pregnancy, pregnancy 
progression, or pregnancy outcomes in pregnant women 
with uterine fibroids. These results thus provide a theoretical 
basis for dydrogesterone treatment (to prevent miscarriage) 
with far-reaching clinical significance.
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